Ticker

Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) shares dropped 25% to 4.25p after the company posted first-half revenues of $1.6 million and flagged slower-than-expected progress in rolling out its kidney disease diagnostic test. The company, which develops the FDA-approved and Medicare-reimbursed kidneyintelX.dkd test for early-stage diabetic kidney disease, said full-year revenue is now expected to reach $4 million,…

Renalytix PLC (AIM:RENX, OTC:RNLXY), the diagnostics company behind the kidney disease risk test kidneyintelX.dkd, has signed up three more US healthcare providers, as it looks to grow uptake of its FDA-approved testing platform. The London and New York-based firm said it had completed clinical integrations with practices in New York, Florida and Tennessee in the final quarter of last year.